Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143

Completed · Phase 1/Phase 2

Conditions studied: Solid Tumor

In brief

Part A (dose-optimization)- to determine the recommended phase 2 dose (RP2D) taking into account dose-limiting toxicity (DLT/s) in Cycle 1, overall safety/tolerability and pharmacokinetic (PK), by optimizing doses of Debio 1143 when combined with the standard dose of nivolumab, as well as treatment compliance in participants with advanced solid malignancies who failed prior systemic standard treatments. Part B (basket trial)- to evaluate the preliminary anti-tumor activity of Debio 1143 at the RP2D in combination with nivolumab at the standard dose, overall and in each participant cohort (Cohort 1: small cell lung cancer \[SCLC\]; Cohort 2: squamous cell carcinoma of the head and neck \[SCCHN\]; Cohort 3: gastrointestinal (GI) cancers with known microsatellite instability-high/mismatch repair deficiency (MSI-H/MMRd) or other deoxyribonucleic acid (DNA) damage repair (DDR) abnormalities, including homologous recombination deficiency (HRD); Cohort 4: platinum-resistant epithelial ovarian cancer \[EOC\], endometrial cancer, primary peritoneal cancer (PPC) or cervical cancer, with known MSIH/MMRd, hereditary/somatic mutations of the breast cancer 1 (BRCA1) and BRCA2 genes or other DNA DDR abnormalities (incl. HRD).

Key facts

Study ID: NCT04122625
Run by: Debiopharm International SA
People needed: 46
Starts: 2019-04-26
Expected to finish: 2022-04-06
Last updated by the study team: 2023-06-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Have received at least one prior line of standard systemic chemotherapy in the advanced/unresectable cancer setting (standard adjuvant/neoadjuvant treatment is acceptable if relapse occurred within six months of treatment end)
Have progressed or relapsed during or after a prior anti-programmed cell death-1 (PD-1)/ programmed cell death-ligand 1 (PD-L1)-based treatment, given either as a single agent or in combination with standard/approved chemotherapy, tyrosine kinase inhibitors (TKIs), radiotherapy (RT) or other monoclonal antibodies (mAbs) that are not known to modulate/inhibit immune checkpoints (CPIs)
Measurable disease (Part B only) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or Gynecologic Cancer Intergroup (GCIG) criteria in Cohort #4 of Part B (if applicable) and documented PD during or after prior PD-1/PD-L1 based therapy

You may not qualify if…

Thoracic or head and neck radiation >30 gray (Gy) within the 3 months prior to Cycle 1 Day 1 (C1D1)
Have received, in total, more than 3 (i.e., Cohorts 1 \& 2) or 4 (i.e., Cohorts 3 \& 4) lines of prior systemic treatments in Part B (including adjuvant or neoadjuvant regimens if relapse within six months prior to C1D1)
Liver cirrhosis Child-Pugh score B or C

Where it is running

University of Florida — Gainesville, Florida, United States
H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States
Rush University Medical Center — Chicago, Illinois, United States
Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
Dana-Farber/Partners Cancer Care — Boston, Massachusetts, United States
Washington University — St Louis, Missouri, United States
Montefiore Medical Center PRIME — The Bronx, New York, United States
UC Health, LLC. — Cincinnati, Ohio, United States
St. Luke's University Health Network — Bethlehem, Pennsylvania, United States
Methodist Hospital, Houston Methodist Cancer Center — Houston, Texas, United States
Georgetown University - Lombardi Comprehensive Cancer Center — Northwest, Washington, United States
Centre Leon Berard — Lyon, France
Institut Universitaire du Cancer de Toulouse Oncopole — Toulouse, France
Institut Gustave Roussy — Villejuif, France
Hospital Vall d'Hebron — Barcelona, Spain
START Madrid, Fundacion Jimenez Diaz — Madrid, Spain
START Madrid, H.U. Sanchinarro — Madrid, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.